IONIS PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Private, Subsidiary

Established: 1989-01-01

Employees: 927

Market Cap: -

Website: http://www.ionis.fr

Clinical Trials

FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

Phase 3

Recruiting

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Placebo
Drug: ION363

First Posted Date: 2021-02-24

Last Posted Date: 2024-11-12

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 95

Registration Number: NCT04768972

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸
Stanford University Medical Center, Palo Alto, California, United States

and more 22 locations

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION904

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ION904
Drug: Placebo

First Posted Date: 2021-02-01

Last Posted Date: 2022-08-09

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 40

Registration Number: NCT04731623

Locations: 🇨🇦
BioPharma Services, Inc., Toronto, Ontario, Canada

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: IONIS-AGT-LRx
Drug: Placebo

First Posted Date: 2021-01-19

Last Posted Date: 2023-02-27

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 160

Registration Number: NCT04714320

Locations: 🇺🇸
Nature Coast Clinical Research - Crystal River, Crystal River, Florida, United States
🇺🇸
Eagle Clinical Research, Chicago, Illinois, United States
🇺🇸
Holston Medical Group, Kingsport, Tennessee, United States

and more 47 locations

A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: ION537

First Posted Date: 2020-12-09

Last Posted Date: 2022-12-21

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 15

Registration Number: NCT04659096

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)

Phase 3

Completed

Conditions: Familial Chylomicronemia Syndrome

Interventions: Drug: Olezarsen
Drug: Placebo

First Posted Date: 2020-09-29

Last Posted Date: 2024-12-13

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 66

Registration Number: NCT04568434

Locations: 🇪🇸
Hospital Abente y Lago, A Coruña, Spain
🇺🇸
Diabetes/Lipid Management & Research Center, Huntington Beach, California, United States
🇺🇸
New York University (NYU) Langone Medical Center, New York, New York, United States

and more 46 locations

A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly

Phase 2

Completed

Conditions: Acromegaly

Interventions: Drug: GHR-LRX

First Posted Date: 2020-08-21

Last Posted Date: 2024-10-03

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 34

Registration Number: NCT04522180

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇱🇹
Vaidoto Urbanaviciaus Individuali imone, Alytus, Lithuania
🇮🇹
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy

and more 19 locations

A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB)

Phase 2

Terminated

Conditions: Chronic Bronchitis
Chronic Obstructive Pulmonary Disease

Interventions: Drug: ION-827359
Drug: Placebo

First Posted Date: 2020-06-22

Last Posted Date: 2022-12-20

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 60

Registration Number: NCT04441788

Locations: 🇩🇪
MECS Research GmbH, Berlin, Germany
🇩🇪
Pneumologisches Studienzentrum Markgrafenstrasse, Berlin, Germany
🇩🇪
Hamburger Institut far Therapieforschung GmbH, Hamburg, Germany

and more 12 locations

A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Refractory Multiple Myeloma
Relapsed Multiple Myeloma

Interventions: Drug: ION251

First Posted Date: 2020-05-21

Last Posted Date: 2024-10-31

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 23

Registration Number: NCT04398485

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States

and more 3 locations

An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema

Phase 2

Active, not recruiting

Conditions: Hereditary Angioedema

Interventions: Drug: Donidalorsen

First Posted Date: 2020-03-13

Last Posted Date: 2024-12-16

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 20

Registration Number: NCT04307381

Locations: 🇳🇱
Ionis Investigative Site, Amsterdam, Netherlands

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Healthy Japanese Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Placebo
Drug: Eplontersen

First Posted Date: 2020-03-10

Last Posted Date: 2022-03-31

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 24

Registration Number: NCT04302064

Locations: 🇺🇸
WCCT Global, Cypress, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy